1. McLeod BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. Best Pract Res Clin Haematol. 2006; 19:157–67.
Article
2. Pandey S and Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012; 52(S1):65S–79S.
3. Fung MK, Grossman BJ, et al. eds. Technical manual. 18th ed.Bethesda: American Association of Blood Banks;2006. p. 678–80.
4. Stafford CT, Lobel SA, Fruge BC, Mofftt JE, Hoff RG, Fadel HE. Anaphylaxis to human serum albumin. Ann Allergy. 1988; 61:85–8.
5. Komericki P, Grims RH, Aberer W, Kränke B. Near-fatal anaphylaxis caused by human serum albumin in fbrinogen and erythrocyte concentrates. Anaesthesia. 2014; 69:176–8.
6. Fujita A, Kitayama M, Hirota K. Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting. J Anesth. 2007; 21:396–8.
Article
7. Ring J, Stephan W, Brendel W. Anaphylactoid reactions to infusions of plasma protein and human serum albumin. Role of aggregated proteins and of stabilizers added during production. Clin Allergy. 1979; 9:89–97.
Article
8. Beavers C, Flinchum D, Ayyoubi MT. Severe intraoperative albumin transfusion reaction and review of the literature. Lab Med. 2013; 44:e129–31.
Article
9. Jung SY, Choi YJ, Lee SH, Kang HR, Suh DI. Successful desensitization of a patient with albumin hypersensitivity. Allergy Asthma Respir Dis. 2017; 5:117–20.
Article
10. McLeod BC. Plasma and plasma derivatives in therapeutic plasmapheresis. Transfusion. 2012; 52(S1):38S–44S.
Article
11. Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol. 2013; 160:434–44.
Article
12. Matejtschuk P, Dash CH, Gascoigne EW. Production of human albumin solution: a continually developing colloid. Br J Anaesth. 2000; 85:887–95.
Article
13. Heinonen J, Peltola K, Himberg JJ, Suomela H. Correlation of hypotensive effect of plasma protein fraction with prekallikrein activator activity: a clinical study in patients having open-heart surgery. Ann Thorac Surg. 1982; 33:244–9.
Article
14. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE Jr, Mozen MM, et al. Hypotension associated with prekallikrein activator (Hage-man-factor fragments) in plasma protein fraction. N Engl J Med. 1978; 299:66–70.
Article
15. Yu MW and Finlayson JS. Stabilization of human albumin by caprylate and acetyltryptophanate. Vox Sang. 1984; 47:28–40.
16. Hossaini AA, Hazeghi K, Amiri P. Experimental induction of caprylate-dependent albumin antibodies. Transfusion. 1977; 17:54–8.
Article
17. Hafer C, Golla P, Gericke M, Eden G, Beutel G, Schmidt JJ, et al. Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int Urol Nephrol. 2016; 48:133–8.
Article
18. Madore F. Plasmapheresis. Technical aspects and indications. Crit Care Clin. 2002; 18:375–92.
19. Myburgh JA and Mythen MG. Resuscitation fuids. N Engl J Med. 2013; 369:1243–51.
20. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg. 2004; 139:552–63.
Article
21. Mitra S and Khandelwal P. Are all colloids same? How to select the right colloid? Indian J Anaesth. 2009; 53:592–607.
22. Harm S, Schildböck C, Hartmann J. Removal of stabilizers from human serum albumin by adsorbents and dialysis used in blood purifcation. PLoS One. 2018; 13:e0191741.